were tested for their ability to induce a protective immune response against intracerebral challenge with neuroadapted strains of MV and canine distemper virus (CDV) in mice. Of the panel of peptides tested, only a chimeric peptide consisting of two copies of a promiscuous T-cell epitope (representing residues 288 to 302 of MV F protein) synthesized at the amino terminus of a B-cell epitope (representing residues 404 to 414 of MV F protein) was able to induce a protective response against challenge with MV and CDV in inbred mice. The protective response induced by this peptide (TTB) was associated with a significant reduction in mortality, histological absence of acute encephalitis, and greatly reduced titers of virus in the brains of TTB-immune mice following challenge compared with the results for nonimmunized controls. A chimeric peptide comprising one copy of the T-cell epitope and one copy of the B-cell epitope (TB) did not induce a protective response. A comparison of the antibody responses induced by the two chimeras suggested that differences in protective efficacy following immunization may be a result of the higher affinity of the antibody induced by the TTB peptide than that of the antibody induced by the TB peptide. In addition, differences in the immunoglobulin G subclass of the antipeptide antibody responses were observed, and these may play a role in the differences in protection observed. These results indicate that appropriately designed synthetic peptides have potential as vaccines for the induction of cross-reactive protection against morbilliviruses.
Measles virus (MV) and canine distemper virus (CDV) are members of the Morbillivirus genus of the Paramyxoviridae family (17) . The surface localization of the hemagglutinin (H) and fusion (F) proteins of these viruses is important in determining their role in mediating virus-cell membrane interactions during infection. The H protein is responsible for the first step in infection, the adsorption of the virus to receptors on the host cell, whereas the F protein is actively involved in the induction of membrane fusion (7) . Passively administered monoclonal antibodies against both H and F neutralize the virus in vitro and protect animals from infection (8, 9) . The importance of antibodies to the F protein is further illustrated by the observation that the immunopathological response of atypical measles is associated with the absence of anti-F antibodies following immunization with formalin-inactivated virus (5, 16) , presumably as a result of the destruction of important immunogenic properties of the glycoprotein by the formalin.
There is considerable sequence homology between the structural proteins of MV and CDV: for example, the F-proteins of the two viruses have 82% sequence homology (3) . In addition, dogs inoculated with MV or with a vaccinia virus recombinant expressing MV H and F proteins survived a lethal challenge with CDV (28) , and partial protection against CDV infection has been demonstrated in mice immunized with a vaccinia virus recombinant expressing MV F protein (29) . Further evidence for the cross-reactivity of the two viruses is provided by the observation that passive transfer to mice of monoclonal anti-MV F antibodies conferred protection against challenge with neuroadapted CDV (13) . Although the widespread use of attenuated measles vaccine has been successful in reducing the incidence of childhood measles in developed countries, the virus still remains one of the major causes of infant mortality in many parts of the world. Therefore, the development of a synthetic peptide vaccine based on the critical epitopes from the structural proteins of the virus is a valid strategy for the control of measles. Synthetic peptides representing specific regions of proteins can induce both humoral and cellular immune responses specific to those proteins (14, 26) , and such observations are important for the development of strategies for the rational design of future vaccines (1) . For synthetic peptides to act as effective immunogens, they must comprise two distinct sites, one to promote B-cell interaction and a second to induce cognate helper T-cell activity (4, 10, 15) . Chimeric peptides comprising both types of epitopes represent immunogens with the potential to elicit antibodies and to prime for memory responses. For chimeric peptides to act as immunogens with potential for vaccine use, attention has to be given to their overall amino acid composition, the number and orientation of the component epitopes, and the use of adjuvants and delivery systems. Recent evidence has illustrated the importance of the orientation of the T-cell epitope and B-cell epitopes from MV proteins in determining the immunogenicity of synthetic constructs and the way in which the chimeric peptides are processed and presented, thus influencing anti-body specificity (18, 19, 22) . Furthermore, the orientation of the T-cell epitope with respect to the B-cell epitope and duplicate copies of the T-cell epitope markedly influence both the affinity and level of antibodies specific for the B-cell epitope (20) .
In the work described here, we investigated the ability of chimeric peptide constructs comprising B-and T-cell epitopes of the F protein of MV to induce protective responses in mice against challenge with neuroadapted strains of MV and CDV.
MATERIALS AND METHODS
Peptides. Residues 288 to 302 of the F protein of MV represent a promiscuous T-cell epitope in mice (21) , which is able to provide help for B-cell epitopes (24) , and this sequence was therefore chosen as the helper T component (T) of the chimeric peptides. The sequence from 288 to 302 contains several class II motifs, i.e., a Rothbard motif, an I-A d motif, and a DR1 -motif, and is amphipathic (21). It does not contain any of the published class I motifs. Residues 404 to 414 of the F protein represent a B-cell epitope (B) which requires a helper T-cell epitope to render it immunogenic (18, 24) . These regions of the F protein of MV are almost identical to those in the F protein of the closely related morbillivirus CDV. In the case of the region represented by residues 288 to 302, there are conserved substitutions in the CDV sequence at positions 291 (I to V) and 301 (G to A) ( Table 1 ). In the case of the region from 404 to 414, there is one conserved substitution in the CDV sequence at position 407 (D to S) ( Table 1) . Peptides representing residues 288 to 302 and residues 404 to 414 were synthesized by manual solid-phase synthesis, using Fmoc chemistry. Chimeric peptides in which one or two copies of the T-cell epitope (288 to 302) were colinearly synthesised at the amino terminus of one or two copies of the B-cell epitope (404 to 414) with two glycines as a spacer were produced (Table 1) . A peptide consisting of two copies of the T-cell epitope was also synthesized. Peptides representing residues 258 to 277 of MV F protein and residues 321 to 336 of MV nucleoprotein (NP) were used as control peptides.
Peptide synthesis was performed by converting Fmoc-protected amino acids to the hydroxybenzotriazol-activated esters by treatment with hydroxybenzotriazol and diisopropylcarbodiimide in dimethyl formamide. The subsequent coupling reactions were performed in dimethyl formamide, and the Fmoc groups were removed with 20% piperidine in dimethyl formamide followed by a series of washes in dimethyl formamide. After synthesis, side-chain-protecting groups were removed and the peptide was cleaved from the support resin with trifluoroacetic acid in the presence of scavengers. After cleavage, the peptides were extracted into diethyl ether and purified by preparative high-pressure liquid chromatography (HPLC), and the purity was assessed by analytical HPLC, amino acid analysis, and fast atom bombardment mass spectrometry.
Mice. Inbred male and female BALB/c (H-2 d ), CBA (H-2 k ), and C57BL/6 (H-2 b ) mice were used in these studies. They were bred and maintained at the Royal Veterinary College, London, United Kingdom.
Viruses. Rodent neuroadapted strains of MV (CAM/RBH strain; kindly provided by U. Liebert, Institut für Virologie und Immunbiologie, Wurzburg, Germany) and CDV (Ondersterpoort strain; kindly provided by F. Wild, Institut Pasteur, Lyon, France) were used in these studies. Stocks of virus were prepared by passage in suckling-mouse brains. Mouse brain homogenates (25%) from infected suckling mice were used as the source of virus and were stored at Ϫ70ЊC.
Immunization and challenge of mice. Mice (3 weeks old) were immunized intraperitoneally with 100 g of peptide TT, TB, TTB, or TBB or with control peptides (MV NP residues 321 to 336 Recovery of virus from brains of infected mice. Serial dilutions of brain homogenate (2 mg of tissue per ml) from infected immunized and nonimmunized mice were adsorbed onto Vero cells in 96-well microtiter plates in 199 medium. The cultures were monitored daily for cytopathic effect and titers were determined after 4 to 6 days (12).
Histological testing. Mice were killed with ether, and their brains were immediately immersed in freshly prepared 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 48 to 96 h and embedded in paraffin. Sections (20 m) were stained with hematoxylin and eosin.
Antibody assays. (i) ELISA. Antipeptide and antivirus antibody activity in serum samples obtained from immunized mice before and after virus challenge was assessed by a solid-phase enzyme-linked immunosorbent assay (ELISA) with microtiter plates (Nunc, Roskilde, Denmark) coated overnight at 4ЊC with 50 l of a 5-g/ml solution of the appropriate peptide per well or 50 l of MV or CDV (2 ϫ 10 4 PFU/ml) in 0.1 M carbonate-bicarbonate buffer per well (pH 9.6). The plates were washed with tap water, and the wells were blocked by incubation at 37ЊC for 2 h with 1% gelatin in phosphate-buffered saline (pH 7.3). Titers were determined after serial twofold dilutions of sera in phosphate-buffered saline-0.05% Tween 20-0.25% gelatin and incubated for 1 h at 37ЊC. After the plates were washed, 50 l of a 1:1,000 dilution of peroxidase-conjugated rabbit antimouse immunoglobulin G (IgG), IgG1, IgG2a, IgG2b, or IgG3 (Nordic, Tilburg, The Netherlands) was added to each well, and the mixture was incubated for 1 h at 37ЊC. Unbound conjugate was removed by washing, and bound enzyme was detected by the addition of 50 l of a solution of 0.04% o-phenylenediamine-0.004% hydrogen peroxidase in citrate-phosphate buffer per well. After 10 min, the reaction was stopped by the addition of 25 l of 2 M sulfuric acid per well, and A 492 values were determined on a Titertek Multiskan (Flow Laboratories, Irvine, Scotland). Titers are expressed as log 10 of the reciprocal of the dilution of the antiserum giving an optical density of 0.2 at 492 nm.
(ii) Affinity determination. The affinity of the anti-chimera antibodies for the peptide from residues 404 to 414 was determined by the double-isotope globulin precipitation assay (25) in which 22 Na is used as a volume marker. Appropriate dilutions of antisera were mixed with a range of 10 antigen concentrations containing a constant trace amount of 125 I-labelled peptide and increasing concentrations of unlabelled peptide. After incubation at 4ЊC for 1 h, concentrations of free and antibody-bound peptides were determined at equilibrium by precipitation of the antibody-peptide complexes with 50% saturated ammonium sulfate.
Affinity values for the binding of peptide were calculated from the following form of the Langmuir equation, derived from the mass action equation:
where b is peptide bound by antibody, Abt is the total number of antibodycombining sites, Ag is the free-peptide concentration, and K is an equilibrium constant or affinity. Lymphocyte stimulation assays. Spleens from TTB-immunized mice were removed aseptically, pooled, and teased, and cells were collected by centrifugation. Erythrocytes were lysed with ACK lysis buffer (0.15 M NH 4 Cl, 0.01 M Na 2 EDTA, 1 M KHCO 3 ). Cells were washed twice in RPMI 1640 medium and then resuspended in complete medium (RPMI 1640 medium supplemented with 1% autologous serum, 2 mM L-glutamine, 10 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid [HEPES] buffer, and 100 IU of penicillin or streptomycin per ml). Viable mononuclear cells were counted by using the eosin stain (0.2% [wt/vol] eosin), and cells were adjusted to 10 6 cells per ml. A 200-l volume of cell suspension was placed in each well of a 96-well round-bottomed microtiter plate and incubated in the presence of various concentrations of peptide (0.1 to 20 g per well) or of heat-inactivated CDV (0.2 to 2 ϫ 10 2 PFU per well) in a humidified 5% CO 2 atmosphere at 37ЊC for 5 days. At 18 h before the end of the culture, the cells were pulsed with 1 Ci of [ 3 H]thymidine. The cells were harvested with an Ilacon harvester, and [ 3 H]thymidine incorporation was assessed with a ␤-spectrometer (Beckman). Data are presented as stimulation indices, which represent the ratio of the mean counts per minute of triplicate cultures at each peptide concentration to the mean counts per minute of triplicate cultures in the absence of peptide.
Statistics. The significance of differences in survival following viral challenge between immunized and nonimmunized mice was analyzed by the Fisher-Irwin exact test.
RESULTS

Inbred BALB/c (H-
, and C57BL/6 (H-2 b ) mice were infected intracranially under halothane anesthesia with 10 4 PFU of CDV or MV in 25 to 30 l. Groups of eight 3-week-old C57BL/6 mice were immunized intraperitoneally with each of the peptides TTB, MVF-258, and MVNP-321 (Table 1) . At 3 weeks after immunization, the mice were chal- However, following immunization with the chimeric TTB peptide, the percent survival was significantly higher (P Ͻ 0.015). C57BL/6 mice immunized with the TTB peptide also showed a greater percent survival following challenge with MV than did mice immunized with the control MVNP-231 peptide or with FCA alone, although a maximum of only 50% of the animals died (Fig. 2) .
In a more extensive series of experiments, groups of eight C57BL/6 mice were immunized with the panel of peptides described in Table 1 . Immunization with peptides T, TB, and TBB conferred no significant protection against the development of encephalitis compared with that in control, unimmunized animals. However, immunization with the TTB peptide resulted in a significant reduction in mortality compared with controls ( Fig. 3 ; P Ͻ 0.024 by the Fisher-Irwin exact test). Mice which survived virus challenge (seven of nine TTB-immunized mice and two of eight TB-immunized mice) showed no significant decline in body weight, whereas mice which ultimately died following challenge (two of nine TTB-immunized mice and six of eight TB-immunized mice) showed a progressive and severe decline in body weight (data not shown).
Immunization with the TT peptide also resulted in a reduction in mortality compared with the controls, but the difference was not significant (P Ͻ 0.13). The protective effect of immunization with TTB has been repeated in three further experiments with similar numbers of animals.
Groups of TTB-immunized CBA mice were also challenged with CDV and showed significantly lower mortality following challenge than did the controls (P Ͻ 0.03). Although TTBimmunized BALB/c mice showed greater resistance to challenge than did the controls, the overall susceptibility of this strain of mice to CDV-induced encephalitis was low and the differences were not significant (P Ͻ 0.11) ( Table 2) .
When CBA and C57BL/6 mice were challenged with MV, the overall incidence of fatal encephalitis was lower than that observed following challenge with CDV. However, immunization with the TTB peptide resulted in a statistically significant (P Ͻ 0.05) lower incidence of mortality compared with that seen in MV-challenged control mice. As was observed for CDV, the induction of encephalitis with MV was lower in BALB/c mice than in the other two strains tested, and although immunization with TTB reduced the mortality rate compared with that seen in control animals, the differences were not significant ( Table 2 ). CDV and MV were recovered from brain homogenates of nonimmunized, virus-challenged C57BL/6 mice with titers of 5 ϫ 10 4 and 1.2 ϫ 10 3 PFU/mg of tissue, respectively. However, only 5 PFU of CDV per mg of tissue and 12 PFU of MV per mg were obtained from TTB-immunized, virus-challenged mice. Neither CDV nor MV could be recovered from the spleen, liver, or kidneys of immunized or unimmunized virus-challenged mice.
Sections of brains from peptide-immunized and control MVand CDV-challenged C57BL/6 mice were studied histologically following staining with hematoxylin and eosin. Brains from seven of a group of eight control, unimmunized CDVchallenged mice showed histological features of acute encephalitis with widespread mononuclear cell infiltration in the grey matter, meninges, and ventricles of both cerebral hemispheres with perivascular cuffing (Fig. 4a, c , and e). These observations are consistent with those described in rats infected with MV (11). However, sections of brains from eight TTB-immune virus-challenged mice showed no evidence of acute encephalitis (Fig. 4f) (apart from mild inflammation at the site of virus injection), and the histological appearance was comparable to that seen in control, unimmunized, uninfected mice (Fig. 4b  and d) .
Anti-TTB peptide antibody levels in sera from peptide-immunized C57BL/6 and control mice pre-and post-CDV challenge were assessed by ELISA. Anti-TTB antibody titers in immunized mice were boosted following challenge with CDV (log 10 anti-TTB titers: prechallenge, 2.5 Ϯ 0.75; postchallenge, 3.7 Ϯ 0.25). In the two unimmunized mice which survived up to 14 days after CDV challenge, low levels of anti-TTB antibody were detected (average log 10 titer, 1.6).
The ability of the anti-TTB peptide antibodies to react with MV and CDV was assessed by ELISA. As shown in Fig. 5 , anti-TTB antibodies raised in C57BL/6 mice cross-reacted with MV and CDV.
Previous studies (20) have demonstrated that following immunization with the TTB chimeric peptide, the affinity of antibodies to the B-cell epitope of the chimera was significantly higher than the affinity of anti-B antibodies induced following immunization with the TB chimera. The affinity of antibodies for the peptide from residues 404 to 414 in pools of sera from TTB-and TB-immunized C57BL/6 mice was assessed prior to virus challenge. The affinities of the antibodies for this peptide in sera from TTB-immunized and TB-immunized mice were 1.42 ϫ 10 7 and 6.9 ϫ 10 6 M
Ϫ1
, respectively, consistent with the earlier findings (20) . The IgG subclass distribution of antichimera antibodies in these sera was also analyzed. Antichimera antibodies in TTB-immunized mice were predominantly of the IgG1 and IgG2a subclasses, but anti-TTB antibodies in the IgG2b and IgG3 subclasses were also detected. In TB-immunized mice, the antibodies to the chimera were predominantly of the IgG2a subclass and there were no detectable antibodies in the IgG1, IgG2b, and IgG3 subclasses ( Table 3) .
The demonstration that the chimeric peptide TTB induced high-affinity antibodies which cross-reacted with both MV and CDV suggests that antibody responses may well be the mechanism by which this peptide confers protection. Accordingly, three groups of 2-week-old C57BL/6 mice received either anti-MV serum, anti-TTB serum, or normal mouse serum and were challenged intracranially with MV. As shown in Fig. 6 , the passive transfer of either anti-MV or anti-TTB led to significant protection of C57BL/6 mice against MV encephalitis (P Ͻ 0.05). Spleen cells from TTB-immunized C57BL/6 mice that survived challenge with CDV were taken 4 weeks after the challenge and cultured in vitro with the TTB peptide and with CDV. The cells showed a dose-related in vitro proliferative response to both the TTB peptide and CDV (Fig. 7) .
DISCUSSION
Immunogenic chimeric peptides composed of amino acid sequences representing T-and B-cell epitopes from the MV F protein were assessed for their ability to induce a protective immune response against encephalitis induced by intracranial challenge with two morbilliviruses, MV and CDV. The peptides chosen for inclusion in the chimeras were those which had previously been shown to induce both B-and T-cell-mediated responses to MV in several inbred strains of mice (18, 21) . Of the panel of peptides tested, only one, the chimera containing two copies of the T-cell epitope from residues 288 to 302 and one copy of the B-cell epitope from residues 404 to 414 from MV F protein (TTB), induced a protective immune response against challenge with the viruses. To define the minimum sequence from the chimeric peptide capable of inducing a protective response, C57BL/6 mice were immunized with a panel of peptides representing different sequences from TTB. Of the peptides tested, only the TTB peptide induced an immune response which conferred protection against challenge (Fig. 3) . Immunization with the T-cell epitope alone, with a chimera composed of two copies of the T-cell epitope, or with a chimera containing two copies of the B-cell epitope and one copy of the T-cell epitope (TBB) did not affect the response to the virus challenge. In addition, immunization with the closely related TB peptide, which had previously been shown to induce an antibody response that reacted with the B-cell epitope and with the virus (18), did not confer a protective immune response. It should be pointed out that although the anti-TTB antibodies cross-react with MV and CDV in ELISA, we were unable to demonstrate in vitro virus neutralization activity of antichimera antibodies induced by either TB or TTB. However, the two immunogens did induce antibodies with differing affinities for the B-cell epitope from residues 404 to 414, confirming our previous observations that the orientation and number of copies of epitopes in chimeric immunogens affect both the qualitative and quantitative aspects of the antibody response (20) . It is attractive to speculate that the difference in protective efficacy of the TB and TTB peptides relates to the ability of the TTB peptide to induce an antibody response with a significantly higher affinity for the B-cell epitope than that (20, 27) . The presence of two copies of the T-cell epitope may enhance T-B collaboration and thus lead to increased T-cell help and hence to a high antibody affinity. In addition, a chimeric peptide with two copies of the T-cell epitope may adopt a conformation which favors moreeffective binding of the B-cell epitope to B-cell surface Ig receptors, again enhancing its immunogenicity. It is also important to recognize that the sequence from 404 to 414 is located in a region of the F molecule which, in the closely related Sendai virus, has been suggested to be close to the amino terminus of the F1 protein (23) . Antibodies to this region may thus interfere with or inhibit the fusion process, and the efficacy of this inhibition would clearly be affected by the affinity of the antibodies. Work is currently in progress to assess the role of the affinity of the antibody against the B-cell epitope in protection in this model system by using the passive transfer of antibodies of defined affinity. The observation that immunization with the TTB chimeric peptide led to a predominantly IgG1 and IgG2a antibody response whereas immunization with the TB chimera resulted in a predominantly IgG2a response suggests a differential activation of helper T-cell subsets following immunization with the two chimeric peptides. It is thus possible that in addition to the importance of antibody affinity, the ability of the TTB peptide to induce a protective response is related to its ability to induce a Th2 T-cell response (IgG1). In this context, it is interesting that IgG1 antibodies to Schistosoma mansoni cercariae, but not those of the other subclasses, were protective against challenge with the parasite (6). Conversely, IgG2a (but not IgG1) antibodies protect mice against lymphocytic choriomeningitis virus (2). Clearly, the role of antibody isotypes and subclasses in protective immune responses requires further investigation.
Although mice immunized with the chimeric TT peptide had a decreased mortality following CDV challenge compared with control animals, the level of protection induced was not statistically significant. These data suggest that it is the presence of two copies of the T-cell epitope and one copy of the B-cell epitope on the same peptide which is critical for the induction of a protective immune response against CDV challenge in C57BL/6 mice. The possibility exists that immunization with the TTB peptide induced a cytotoxic T-cell response which conferred protection against virus challenge. The work described in this report does not address this question, but in preliminary work we have been unable to show the induction of peptide-specific CD4 ϩ or CD8 ϩ cytotoxic T-cell responses following immunization with the TTB peptide (unpublished observations). In addition, the experiments in which anti-TTB peptide antibodies are passively transferred to C57BL/6 prior to challenge with MV (Fig. 6 ) clearly demonstrate that antibodies are capable of conferring protection in the absence of a cytotoxic T-cell response.
One potential limitation to the use of synthetic peptides as vaccines is the effect that major histocompatibility complex restriction may have on the induction of an immune response to the peptide. However, the T-cell epitope used to produce the TTB chimeric construct employed in these studies has been shown to be a promiscuous epitope, inducing T-cell help in several inbred mouse strains (21) . Indeed, in the work described here, the TTB peptide induced a protective response against CDV and MV challenge in C57BL/6 and CBA mice. In addition, anti-TTB antibody responses in TTB-immunized mice were boosted after challenge with CDV, suggesting that immunization with the peptide primed the mice for a subsequent response to the virus. This ability of the peptide to prime for a subsequent response to the virus was further confirmed by the demonstration that TTB-immune lymphocytes were stimulated to proliferate in vitro following stimulation with CDV. However, we failed to demonstrate a proliferative response of TTB-primed lymphocytes to MV (data not shown).
The results presented in this paper, to our knowledge, represent the first description of the use of a synthetic peptide immunogen to induce a protective immune response against challenge with neuroadapted MV and CDV. Furthermore, the results also demonstrate that the component sequences in the peptides which were chosen as representing epitopes from MV F protein also induce immune responses which are cross-protective and are effective against challenge with CDV, and they highlight the potential importance of antibodies to the F protein in protection.
